Arachidonate 5-lipoxygenase (5-LO) promoter genotype and risk of myocardial infarction: A case-control study

Atherosclerosis

Volumn 199, Issue 2, 2008, Pages 328-332

  Maznyczka, Annette ^a   Braund, Peter ^a   Mangino, Massimo ^a   Samani, Nilesh J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

5 Lipoxygenase; Atherosclerosis; Genetics; Leukotrienes; Myocardial infarction

Indexed keywords

ADULT; ALLELE; ARACHIDONATE 5 LIPOXYGENASE GENE; ARTICLE; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RISK;

ADULT; ALLELES; ARACHIDONATE 5-LIPOXYGENASE; BINDING SITES; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; RISK; SP1 TRANSCRIPTION FACTOR;

EID: 45649085560     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.11.027     Document Type: Article

References (30)

1. Boersma E., Mercado N., Poldermans D., et al. Acute myocardial infarction. Lancet 361 (2003) 847-858
2. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1875
3. Davidson J., and Rotondo D. Lipid metabolism, 5-lipoxygenase, 12/15-lipoxygenase and atherogenesis. Curr Opin Lipidol 18 (2007) 107-109
4. Funk C.D. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 4 (2005) 664-672
5. Lynch K.R., O'Neill G.P., Liu Q., et al. Characterisation of the human cysteinyl leukotriene cysLT1 receptor. Nature 399 (1999) 789-793
6. Heise C.E., O'Dowd B.F., Figueroa D.J., et al. Characterisation of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275 (2000) 30531-30536
7. 4 that mediates chemotaxis. Nature 387 (2000) 620-624
8. 4 receptor BLT2: a new therapeutic target in inflammation and immunological disorders. J Exp Med 192 (2000) 421-432
9. Laitinen L.A., Laitinn A., Haahtela T., et al. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 341 (1993) 989-990
10. Barnes N.C., Piper P.J., and Costello J.F. Comparative effects of inhaled leukotriene C4, leukotriene D4 and histamine in normal human subjects. Thorax 39 (1984) 500-504
11. Nayak A. A review of montelukast in the treatment of asthma and allergic rhinitis. Expert Opin Pharmacother 5 (2004) 679-686
12. Mehrabian M., Allayee H., Wong J., et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 91 (2002) 120-126
13. Spanbroek R., Gräbner R., Lötzer K., et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 100 (2003) 1238-1243
14. Aiello R.J., Bourassa P.A., Lindsey S., et al. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 22 (2002) 443-449
15. 4 and BLT1 in smooth muscle cell recruitment. Circulation 112 (2005) 578-586
16. Hoshiko S., Rådmark O., and Samuelsson B. Characterization of the human 5-lipoxygenase gene promoter. Proc Natl Acad Sci USA 87 (1990) 9073-9077
17. Silverman E.S., Du J., De Sanctis G.T., et al. Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants. Am J Respir Cell Mol Biol 19 (1998) 316-323
18. In K.H., Asano K., Beier D., et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 99 (1997) 1130-1137
19. Dwyer J.H., Allayee H., Dwyer K.M., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid and atherosclerosis. N Engl J Med 350 (2004) 29-37
20. Mitchell J.R.A., and Schwartz C.J. Relationship between arterial disease in different sites: a study of the aorta and coronary, carotid, and iliac arteries. BMJ 1 (1962) 1293-1301
21. Iglesias del Sol A., Bots M.L., Grobbee D.E., Hofman A., and Witteman J.C.M. Carotid intima-media thickness at different sites: relation to incident myocardial infarction. The Rotterdam study. Eur Heart J 23 (2002) 934-940
22. Chambless L.E., Heiss G., Folsom A.R., et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the atherosclerosis risk in communities (ARIC) study, 1987-1993. Am J Epidemiol 146 (1997) 483-494
23. Steeds R., Addams M., Smith P., Channer K., and Samani N.J. Distribution of tissue plasminogen activator insertion/deletion polymorphism in myocardial infarction and control subjects. Thromb Haemost 79 (1998) 980-984
24. Brouilette S., Singh R.K., Thompson J.R., Goodall A.H., and Samani N.J. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol 23 (2003) 842-846
25. Nomenclature and criteria for diagnosis of ischemic heart disease: report of the joint international society and federation of cardiology/world health organization task force on standardization of clinical nomenclature. Circulation 59 (1979) 607-609
26. Sayers I., Barton S., Rorke S., et al. Promoter polymorphisms in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population. Clin Exp Allergy 33 (2003) 1103-1110
27. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447 (2007) 661-678
28. González P., Reguero J.R., Lozano I., Morís C., and Coto E. A functional Sp1/Egr1-tandem repeat polymorphism in the 5-lipoxygenase gene is not associated with myocardial infarction. Int J Immunogenet 34 (2007) 127-130
29. Drazen J.M., Yandava C.N., Dubé L., et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 22 (1999) 168-170
30. Kalayci O., Birben E., and Sackesen C. ALOX5 promoter genotype, asthma severity and LTC production by eosinophils. Allergy 61 (2006) 97-103